Induces ADCC, ADCP and CDC against CD38+ tumour cells (35). Similarly to daratumumab, isatuximab also induces lysis of CD38+ Tregs, and increases the frequency of CD8+ T cells (36). This evidence concerns the gene CD38 and neoplasm.